乳腺癌的分子诊断  

Molecular diagnosis of breast cancer

作　　者：何涛君[1] 吴正林[1] 

机构地区：[1]广东医学院附属深圳市福田区人民医院检,518033

出　　处：《国际肿瘤学杂志》2013年第4期283-286,共4页Journal of International Oncology

摘　　要：乳腺癌在发生发展过程中有许多相关基因、蛋白质及细胞因子发生改变，对这些标志物的检测将对乳腺癌的诊断、治疗及判断预后有重要作用。近年来，随着分子生物学的发展，各地相继开展了一些乳腺癌相关基因及蛋白的检测项目，如雌激素受体（ER）、孕激素受体（PR）、HER-2、p53等。但各地区、各医院检测内容却不尽相同，且临床上尚无统一标准。There are many associated genes,proteins and cytokines altering in the genesis and develop- ment of breast cancer. It is very important to detect these tumor markers for the diagnosis, therapy and progno- sis prodicting of breast cancer. In recent years, following by molecular biology development, the detection items on associated genes and proteins of breast cancer have been carried out one after another, such as ER, PR, HER-2 ,p53 and so on. However, these detection contents are not identical by each other from different areas and hospitals, without unified standard.

关 键 词：乳腺肿瘤 肿瘤标记 生物学 基因 肿瘤 

分 类 号：R737.9[医药卫生—肿瘤]